← Back to Clinical Trials
Recruiting NCT01441089

NCT01441089 Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT01441089
Status Recruiting
Phase
Sponsor National Cancer Institute (NCI)
Condition Prostate Cancer
Study Type OBSERVATIONAL
Enrollment 1,100 participants
Start Date 2012-05-21
Primary Completion

Eligibility & Interventions

Sex All sexes
Min Age 3 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 1,100 participants in total. It began in 2012-05-21.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Background: \- Some genes may be associated with a greater chance of side effects during cancer treatment. These genes may also make certain treatments less effective. Researchers want to collect blood or cheek swab samples from people having cancer treatment to study these genes. Objectives: \- To obtain a blood or cheek swab sample to study genetic differences that may affect cancer treatment. Eligibility: \- Individuals with cancer who are being treated at the National Cancer Institute. Design: * Participants will provide a blood sample for study. * Participants who have blood-based cancer, such as leukemia, will provide a cheek swab sample. * If the blood or cheek swab sample does not have enough genetic material for analysis, an additional sample may be collected.

Eligibility Criteria

* INCLUSION CRITERIA: * Any individual currently enrolled in an NIH intramural research program clinical trials receiving treatment. * Ability of participant or Legally Authorized Representative (LAR) to understand and be willing to sign the informed consent document. * Age \>= 3 years old EXCLUSION CRITERIA: -N/A

Contact & Investigator

Central Contact

Deneise C Francis, R.N.

✉ deneise.francis@nih.gov

📞 (240) 858-3974

Principal Investigator

William D Figg, Pharm.D.

PRINCIPAL INVESTIGATOR

National Cancer Institute (NCI)

Frequently Asked Questions

Who can join the NCT01441089 clinical trial?

This trial is open to participants of all sexes, aged 3 Years or older, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT01441089 currently recruiting?

Yes, NCT01441089 is actively recruiting participants. Contact the research team at deneise.francis@nih.gov for enrollment information.

Where is the NCT01441089 trial being conducted?

This trial is being conducted at Bethesda, United States.

Who is sponsoring the NCT01441089 clinical trial?

NCT01441089 is sponsored by National Cancer Institute (NCI). The principal investigator is William D Figg, Pharm.D. at National Cancer Institute (NCI). The trial plans to enroll 1,100 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology